T2 Biosystems Inc logo

T2 Biosystems Inc

FRA:3T2 (USA)  
€ 4.06 (-3.56%) Jun 7
At Loss
Market Cap:
€ 67.24M ($ 72.71M)
Enterprise V:
€ 106.99M ($ 115.70M)
Volume:
780.00
Avg Vol (2M):
1.05K
Also Trade In:
PE Ratio PS Ratio PB Ratio Price-to-FCF Market Cap
Current and historical daily PE Ratio for T2 Biosystems Inc ( ) from 2014 to Jun 09 2024. The price to earnings ratio is calculated by taking the current stock price and dividing it by the most recent trailing twelve-month earnings per share (EPS) number. The data is updated every 20 minutes during market hours. The PE ratio can be viewed as the number of years it takes for the company to earn back the price you pay for the stock. Therefore, lower-P/E stocks are more attractive than higher P/E stocks so long as the PE ratio is positive. Also for stocks with the same PE ratio, the one with faster growth business is more attractive. T2 Biosystems stock (FRA:3T2) PE ratio as of Jun 09 2024 is 0. More Details

T2 Biosystems Inc (FRA:3T2) PE Ratio (TTM) Chart

To

T2 Biosystems Inc (FRA:3T2) PE Ratio (TTM) Historical Data

Total 1291
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 15
T2 Biosystems PE Ratio (TTM) Historical Data
Date PE Ratio (TTM) Data Date PE Ratio (TTM) Data
2024-06-10 At Loss 2024-04-08 At Loss
2024-06-07 At Loss 2024-04-05 At Loss
2024-06-06 At Loss 2024-04-04 At Loss
2024-06-05 At Loss 2024-04-03 At Loss
2024-06-04 At Loss 2024-04-02 At Loss
2024-06-03 At Loss 2024-04-01 At Loss
2024-05-31 At Loss 2024-03-29 At Loss
2024-05-30 At Loss 2024-03-28 At Loss
2024-05-29 At Loss 2024-03-27 At Loss
2024-05-28 At Loss 2024-03-26 At Loss
2024-05-27 At Loss 2024-03-25 At Loss
2024-05-24 At Loss 2024-03-22 At Loss
2024-05-23 At Loss 2024-03-21 At Loss
2024-05-22 At Loss 2024-03-20 At Loss
2024-05-21 At Loss 2024-03-19 At Loss
2024-05-20 At Loss 2024-03-18 At Loss
2024-05-17 At Loss 2024-03-15 At Loss
2024-05-16 At Loss 2024-03-14 At Loss
2024-05-15 At Loss 2024-03-13 At Loss
2024-05-14 At Loss 2024-03-12 At Loss
2024-05-13 At Loss 2024-03-11 At Loss
2024-05-10 At Loss 2024-03-08 At Loss
2024-05-09 At Loss 2024-03-07 At Loss
2024-05-08 At Loss 2024-03-06 At Loss
2024-05-07 At Loss 2024-03-05 At Loss
2024-05-06 At Loss 2024-03-04 At Loss
2024-05-03 At Loss 2024-03-01 At Loss
2024-05-02 At Loss 2024-02-29 At Loss
2024-05-01 At Loss 2024-02-28 At Loss
2024-04-30 At Loss 2024-02-27 At Loss
2024-04-29 At Loss 2024-02-26 At Loss
2024-04-26 At Loss 2024-02-23 At Loss
2024-04-25 At Loss 2024-02-22 At Loss
2024-04-24 At Loss 2024-02-21 At Loss
2024-04-23 At Loss 2024-02-20 At Loss
2024-04-22 At Loss 2024-02-19 At Loss
2024-04-19 At Loss 2024-02-16 At Loss
2024-04-18 At Loss 2024-02-15 At Loss
2024-04-17 At Loss 2024-02-14 At Loss
2024-04-16 At Loss 2024-02-13 At Loss
2024-04-15 At Loss 2024-02-12 At Loss
2024-04-12 At Loss 2024-02-09 At Loss
2024-04-11 At Loss 2024-02-08 At Loss
2024-04-10 At Loss 2024-02-07 At Loss
2024-04-09 At Loss 2024-02-06 At Loss

T2 Biosystems Inc (FRA:3T2) PE Ratio (TTM) Comparison

Company Market Cap(Mil) PE Ratio (TTM)

Business Description

Business Description

T2 Biosystems Inc logo
T2 Biosystems Inc
NAICS : 325413 SIC : 2835
ISIN : US89853L1044
Description
T2 Biosystems Inc is a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes. It is dedicated to improving patient care and reducing the cost of care by helping clinicians effectively treat patients faster than ever before. The company's products include the T2Dx Instrument, the T2Bacteria Panel, the T2Candida Panel, the T2Resistance Panel, and the T2Biothreat Panel, and are powered by the proprietary T2 Magnetic Resonance technology.